Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10618MR)

This product GTTS-WQ10618MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10618MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10261MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ1689MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ229MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ15917MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1607MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ4704MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ3249MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ3201MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW